Vir Biotechnology 2026 Q3 Earnings Call
Review the key takeaways and the transcript of this earnings call.
- Vir Biotechnology reported 3rd quarter 2026 R&D expense of $80 million, compared with $151 million for the same period in 2025; the reduction was primarily driven by a one-time $75 million milestone payment recognized in the 3rd quarter of 2025 following the first patient dose with VIR-5525.
- SG&A expense was $24 million, compared with $22 million for the same period in 2025, primarily due to higher advisory and legal fees.
- Vir ended the quarter with $901 million in cash, cash equivalents, and investments; that balance did not include the $90 million from the Gilead collaboration received in October.
- The Gilead agreement provided $90 million, consisting of $65 million upfront and a $25 million equity investment at a 30% premium; Vir is also eligible for up to $45 million in near-term preclinical milestones, up to $1.74 billion in additional development, regulatory, and commercial milestones, and tiered high single to low double-digit royalties.
- The 20% pass-through economics to Sanofi had expired and were no longer in effect at the time of the Gilead agreement, so milestone payments from the collaboration will not be shared with Sanofi.
- Vir reported that the FDA granted fast-track designation to VIR-5500 for late-line metastatic castration-resistant prostate cancer, and Astellas said VIR-5500 had achieved proof of concept.
- The FDA's feedback on the VR-5818 monotherapy arm led Vir to refine the study by adding backfill cohorts in a more homogeneous patient population; the dataset is not yet complete.
STOCKNOW INSIGHTS
Continue with outlook and guidance.
Log in to unlock executive comments and Q&A highlights.
Log in for the full summaryStockNow uses AI to translate and summarize earnings calls. Accuracy and completeness are not guaranteed.
Transcript
Preview the first fifteen paragraphs, organized by speaker.
Hello, and welcome to Vir Biotechnology's third quarter 2026 financial results and corporate update conference call. As a reminder, this call is being recorded. At this time, all participants are in a listen-only mode. After the speaker's prepared remarks, there will be a question-and-answer session. I will now turn the call over to Kiki Patel, Head of Investor Relations.
You may begin, Kiki. Thank you, operator, and welcome, everyone.
Earlier today, we issued a press release reporting our third quarter 2026 financial results and corporate update. Before we begin, I'd like to remind everyone that some of the statements we are making today are forward-looking statements under applicable securities laws. Forward-looking statements include, but are not limited to, statements regarding the therapeutic and commercial potential of our clinical and preclinical programs, our development plans and timelines, our collaborations with other companies, our cash runway and capital allocation priorities, and as otherwise described in the legal disclaimers accompanying our public presentations. These forward-looking statements involve substantial risks and uncertainties, which are described in our reports filed with the Securities and Exchange Commission, including our Forms 10-K, 10-Q, and eight-K, and could cause future results, performance, or achievements to differ significantly from those expressed or implied by such forward-looking statements.
Joining me on today's call from Vir Biotechnology are Dr. Marianne DeBacker, our President and Chief Executive Officer, and Aziz Sawaf, our Chief Financial Officer. The agenda for our call today is as follows. First, Marianne will provide a strategic update on where Vir Biotechnology stands today, including an overview of our phase III registrational program in hepatitis delta. Next, she will review the latest updates across the PRO-XTEN dual-masked T-cell engager programs and present the highlights of our recently announced preclinical collaboration with Gilead. Next, Aziz will review the financial terms of our recent collaboration with Gilead and provide a summary of our third quarter 2026 financial results. Finally, Marianne will close the call, and we'll open the line for Q&A. With that, I'll now turn the call over to Marianne.
Thank you, Kiki. Good afternoon, everyone, and thank you for joining us for Vir Biotechnology's third quarter 2026 financial results conference call. We are entering a pivotal period for Vir Biotechnology, with the potential to transform hepatitis delta treatment while building a differentiated oncology franchise. Today, I will highlight significant progress across both those areas and why we believe Vir Biotechnology is well-positioned for meaningful value creation ahead. First, we've expanded our leadership team with the addition of Aziz Sawaf as Chief Financial Officer and Dr. David Liu as Chief Medical Officer. Both bring more than 20 years of experience in their respective fields, further bolstering our capabilities as we enter an important period for Vir Biotechnology. With our leadership team strengthened, we are well-positioned to execute against the significant opportunities and catalysts ahead. Second, our hepatitis delta program continues to advance through phase III development.
We expect to report top-line data from ECLIPSE 1 this quarter, followed by top-line data from ECLIPSE 2 and ECLIPSE 3 in the first quarter of 2027. We will also present expanded 96-week phase II SOLSTICE results in an oral presentation at AASLD this weekend. Third, we have made meaningful progress across our oncology portfolio. Astellas recently announced that VIR-5500 achieved proof of concept, reinforcing the scientific rationale for advancing the program into late-stage development. In addition, we are pleased to share that the FDA granted fast-track designation to VIR-5500 for the treatment of late-line metastatic castration-resistant prostate cancer. Finally, our recent research collaboration with Gilead underscores the potential of our PRO-XTEN platform and highlights the strength of our integrated AI-enabled capabilities in T-cell engager discovery and optimization.
This collaboration represents the second major external validation of the PRO-XTEN masking technology in the last eight months, following our partnership with Astellas on VIR-5500 in February. Overall, these achievements position us well to execute on our strategic priorities and deliver against the important catalysts ahead. Now, starting with our hepatitis delta program. Chronic hepatitis delta remains one of the most severe and underserved forms of viral liver disease. October was Liver Cancer Awareness Month, and the World Hepatitis Alliance has focused on amplifying the message that hepatitis elimination is liver cancer prevention. Hepatitis delta is associated with a two to six-fold higher risk of liver cancer compared to hepatitis B alone and was classified as carcinogenic by the World Health Organization's International Agency for Research on Cancer last year.
While recent advances have expanded treatment options for patients, there remains a critical need for therapies capable of delivering deeper antiviral activity and more complete disease control. Current approaches have generally focused on decreasing the viral load, but many patients continue to have detectable HDV RNA despite treatment. Hepatologists and treating physicians believe that achieving complete viral elimination to where the virus is undetectable, defined by HDV RNA target not detected, or TND, represents an important next frontier in hepatitis delta care, representing deeper disease control and potential clinical benefit for patients. Building on the encouraging TND results observed in our phase II SOLSTICE trial, the ECLIPSE program is designed to determine whether this approach can consistently deliver profound viral suppression across key populations.
ECLIPSE 1 is designed to provide the first phase III assessment of the proportion of patients who can achieve undetectable HDV RNA after 48 weeks of treatment with our combination regimen of elebsiran and tobevibart. The trial has enrolled approximately 120 participants, randomized 2:1 to monthly subcutaneous dosing of our combination regimen versus deferred treatment in treatment-naïve patients with chronic hepatitis delta. The primary endpoint is a composite of HDV RNA TND together with ALT normalization at week 48. ECLIPSE 2 has enrolled approximately 150 patients who are being randomized 2:1, evaluating the switch to our combination therapy in patients who have an inadequate response to bulevirtide. The primary endpoint for the trial is undetectable virus as defined by HDV RNA TND at week 24. The pace of enrollment we observed in Europe for this trial reflects an important unmet need in patients previously treated with bulevirtide.
ECLIPSE 3 is our pivotal head-to-head trial against bulevirtide in treatment-naïve patients. We have enrolled approximately 100 patients, randomized 2:1 to our combination therapy versus bulevirtide. The primary endpoint for the trial is undetectable virus, as defined by HDV RNA TND at week 48. Together, ECLIPSE 1, 2, and three are expected to provide a comprehensive data package, generating data in treatment-naïve patients switching from bulevirtide, and patients enrolled in a head-to-head comparison against bulevirtide. As bulevirtide utilization grows, physicians will need evidence-based guidance on how best to manage patients who do not achieve adequate viral suppression or who require an alternative treatment approach. To our knowledge, no other late-stage HDV development program is expected to include comparable bulevirtide switch or head-to-head data in its regulatory submission package, potentially providing a uniquely comprehensive evidence base for physicians, payers, and regulators.
Collectively, these studies are designed to position our program at the very forefront of the evolving hepatitis delta treatment landscape and ultimately improve outcomes for patients living with this devastating disease. Turning now to oncology. VIR-5500 is our PRO-XTEN dual-masked PSMA-targeted T-cell engager, which we are advancing in a global co-development and co-commercialization collaboration with Astellas for prostate cancer. Astellas already shared on its earnings call yesterday that VIR-5500 has achieved proof of concept, reinforcing the scientific rationale for advancing the program into registrational trials. This assessment reflects the totality of the clinical, safety, pharmacology, and biomarker data generated to date and supports continued investment in the registrational planning and execution. We also recently announced that the FDA granted fast-track designation to VIR-5500 for the treatment of late-line metastatic castration-resistant prostate cancer, or mCRPC, underscoring VIR-5500's potential to address a significant unmet need in patients who have limited treatment options.
Both of these milestones highlight the strong progress we have made with our partner, Astellas, as we advance the program toward pivotal trials. VIR-5500 is currently being evaluated in a phase I trial as both a monotherapy and combination therapy across six dose expansion cohorts. Indications include taxane-naïve mCRPC, radioligand therapy-naïve mCRPC, radioligand therapy-exposed mCRPC, and metastatic hormone-sensitive prostate cancer. These expansion studies are designed to inform the next phase of development, with the goal of initiating multiple phase III studies spanning both early-line and late-line settings in 2027. In parallel, we are focused on advancing manufacturing readiness in collaboration with Astellas. Importantly, our plans to pursue first-line mCRPC reflect our belief that VIR-5500 has the potential to become a foundational therapy across the prostate cancer treatment continuum. Moving now to VIR-5818, our HER2-targeted T-cell engager.
This program is currently being evaluated in a phase I trial with dose escalation and signal-finding components, both as monotherapy and in combination with pembrolizumab. The trial has enrolled patients with a variety of HER2-expressing cancers. During our last update on the program, we shared encouraging anti-tumor activity and a generally well-tolerated safety profile. While we had previously anticipated providing a data update on the program this year, recent FDA feedback on the monotherapy arm has led us to refine the study. We intend to add backfill cohorts in a more homogeneous patient population to help determine the optimal dose and schedule, which is aligned with FDA's Project Optimus, an initiative to reform the dose optimization and dose selection paradigm in oncology drug development. As a result, the study remains ongoing and the data set is not yet complete.
In parallel, dose escalation and optimization of VIR-5818 in combination with pembrolizumab is ongoing. We anticipate presenting a meaningful update on VIR-5818 at a future scientific conference. Finally, VIR-5525, our EGFR-targeted T-cell engager, continues to progress through dose escalation in both monotherapy and combination therapy with pembrolizumab across lung cancer, colorectal cancer, head and neck squamous cell carcinoma, and cutaneous squamous cell carcinoma. Looking ahead, our preclinical immuno-oncology pipeline is fueling a growing oncology portfolio. We are in a fortunate position where the breadth of opportunities generated by our scientific platform exceeds what we can advance independently, allowing us to be strategic about which programs we progress ourselves. in the first quarter of 2027, we plan to provide a more comprehensive view of the next chapter of our cancer immunotherapy strategy at a virtual research investor event.
We will provide investors with a roadmap for how we plan to build and scale a world-class immuno-oncology franchise. The breadth of our pipeline does not mean we will advance every opportunity ourselves. We intend to be disciplined in how we allocate capital, concentrating investment where our capabilities are most differentiated, and partnering strategically where collaboration can accelerate development, expand reach, and maximize the impact of our platform for patients. Our research collaboration with Gilead is an example of this strategy in action, providing further external validation of the PRO-XTEN platform and the potential to deliver T-cell engagers with an improved safety profile. This preclinical multi-program collaboration leverages Vir Bio's integrated expertise in T-cell engager discovery and protein engineering, our proprietary dAIsY AI platform for rapid multi-parameter optimization of high-quality T-cell engagers, and the PRO-XTEN masking technology to develop next-generation T-cell engagers across multiple solid tumor targets.
FULL TRANSCRIPT
Continue the full translated transcript in StockNow.
Log in to unlock every statement, the English original, and speaker-by-speaker history.
Log in for the full transcriptCall participants
12 people spoke on this call — only 2 are shown here.
PARTICIPANT LIST
View participant details in StockNow.
Log in to see executives and analysts, their roles, and complete speaking history.
Log in to view all participantsKeep exploring
